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Abstract
Background:  Loeys-Dietz syndrome (LDS) is a rare autosomal dominant disorder showing the involvement of
cutaneous, cardiovascular, craniofacial, and skeletal systems. In particular, LDS patients show arterial tortuosity with
widespread vascular aneurysm and dissection, and have a high risk of aortic dissection or rupture at an early age and at
aortic diameters that ordinarily are not predictive of these events. Recently, LDS has been subdivided in LDS type I (LDSI)
and type II (LDSII) on the basis of the presence or the absence of cranio-facial involvement, respectively. Furthermore,
LDSII patients display at least two of the major signs of vascular Ehlers-Danlos syndrome. LDS is caused by mutations in
the transforming growth factor (TGF) beta-receptor I (TGFBR1) and II (TGFBR2) genes. The aim of this study was the
clinical and molecular characterization of two LDS patients.
Methods: The exons and intronic flanking regions of TGFBR1 and TGFBR2 genes were amplified and sequence analysis
was performed.
Results: Patient 1 was a boy showing dysmorphic signs, blue sclerae, high-arched palate, bifid uvula; skeletal system
involvement, joint hypermobility, velvety and translucent skin, aortic root dilatation, tortuosity and elongation of the
carotid arteries. These signs are consistent with an LDSI phenotype. The sequencing analysis disclosed the novel TGFBR1
p.Asp351Gly de novo mutation falling in the kinase domain of the receptor. Patient 2 was an adult woman showing
ascending aorta aneurysm, with vascular complications following surgery intervention. Velvety and translucent skin,
venous varicosities and wrist dislocation were present. These signs are consistent with an LDSII phenotype. In this patient
and in her daughter, TGFBR2 genotyping disclosed in the kinase domain of the protein the novel p.Ile510Ser missense
mutation.
Conclusion: We report two novel mutations in the TGFBR1 and TGFBR2 genes in two patients affected with LDS and
showing marked phenotypic variability. Due to the difficulties in the clinical approach to a TGFBR-related disease, among
patients with vascular involvement, with or without aortic root dilatation and LDS cardinal features, genotyping is
mandatory to clarify the diagnosis, and to assess the management, prognosis, and counselling issues.
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Background
Loeys-Dietz syndrome (LDS) is a rare autosomal domi-
nant disorder characterized by hypertelorism, bifid uvula
and/or cleft palate, and arterial tortuosity with widespread
vascular aneurysm and dissection [1]. LDS shows the
involvement of cutaneous, cardiovascular, craniofacial
and skeletal systems [1,2]. LDS patients have a high risk of
aortic dissection or rupture at an early age and at aortic
diameters that ordinarily are not predictive of these events
[2]. Recently, LDS has been subdivided in LDS type I
(LDSI) and type II (LDSII) on the basis of the presence or
the absence of cranio-facial involvement, respectively [2].
Furthermore, LDSII patients display at least two of the
major signs of vascular Ehlers-Danlos syndrome (vEDS)
[2].
Mutations in the transforming growth factor (TGF) beta-
receptor type I (TGFBR1) and type II (TGFBR2) genes have
been found to cause LDS [1]. Mutations in these genes
were also reported in other syndromes showing cardiovas-
cular involvement, with or without marfanoid habitus or
fulfilled Ghent criteria for Marfan syndrome (MFS) and
variable association with signs characteristic of LDS: MFS
type 2 (MFS2), Furlong syndrome (FS), familial thoracic
aortic aneurysms and dissections type 2 (TAAD2), and
Shprintzen-Goldberg syndrome, the nosological status of
which is still controversial [3-9]. All these syndromes
should be considered as a phenotypic spectrum associated
with aberrant TGFbeta signalling [9].
TGFBR1 and TGFBR2 are transmembrane serine/threo-
nine kinases, both able to bind TGFbeta. Ligand binding
mediates TGFbeta signalling activation [10]. They are
composed of a small cysteine-rich extracellular domain, a
single transmembrane region, and an intracellular kinase
domain [10]. So far, less than 30 TGFBR1 and less than
100  TGFBR2  disease causing mutations have been
described [1-6,11-13].
Here we report the characterization of two Italian LDS
patients and the identification of two novel mutations,
one in the TGFBR1 and the other in the TGFBR2 gene.
Case Presentation
Patient 1 was a seven years old male, born at term after
uncomplicated pregnancy from non-consanguineous par-
ents. At birth, weight and length were normal; he showed
bilateral clubfoot and hand contractures characterized by
camptodactyly and ulnar deviation. At the age of six years
he showed: height 130.5 cm, arm span 129 cm,
upper:lower segment ratio  0.89, muscular hypotrophy;
dolicocephaly, blue sclerae, hypoplastic alae nasi, micro-
retrognathia, high-arched palate, bifid uvula; mild tho-
racic scoliosis and pectus excavatum, pes planus, joint
hypermobility (Beighton score 8/9); velvety and translu-
cent skin (Fig. 1A). Echocardiogram showed bicuspid aor-
tic valve, patent foramen ovale, mild interventricular
septal hypertrophy without outflow obstruction, mild
mitral valve prolapse, aortic root diameter 23 mm and
ascending aorta diameter 21 mm. Magnetic Resonance
Angiography (MRA) displayed tortuosity and elongation
of the basilar and internal carotid arteries with kinking
and coiling of these last. Furthermore, the patient suffered
from allergic asthma and atopic dermatitis.
Patient 2, a 48 years old woman, underwent several vascu-
lar surgery interventions: at the age of 26 years vascular
Clinical and radiographic features of the two LDS Patients Figure 1
Clinical and radiographic features of the two LDS 
Patients. A) Phenotype of Patient 1, showing facial dysmor-
phisms: dolichocephaly, hypoplastic alae nasi, and micro/ret-
rognathia; marfanoid habitus, muscular hypotrophy, mild 
thoracic scoliosis, and pes planus. B) Patient 2: Ascending 
aorta dilatation (i) and MRI axial T1 spin-echo images of the 
ascending aorta at the level of re-implanted coronary arter-
ies, before (ii) and after (iii) gadolinium: a periaortic collec-
tion is visible (arrows), with contrast medium outside the 
aortic graft, due to detachment of re-implanted left coronary 
artery. C) Translucent skin with subcutaneous visible veins 
and flat feet in Patient 2.Orphanet Journal of Rare Diseases 2009, 4:24 http://www.ojrd.com/content/4/1/24
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prosthesis replacement of the ascending aorta with Bentall
technique (composite graft and coronary arteries reim-
plant) for aortic aneurysm; eight years later, surgery for
haematoma consequent to suture dehiscence at the level
of the left coronary ostium; at the age of 43 years surgical
repair of acute dissection starting from the distal anasto-
mosis of the aortic graft extended to the abdominal aorta;
at the age of 44 years, endovascular treatment with stent-
graft of the descending aorta for increase of descending
thoracic false lumen (Fig 1B). The patient showed: height
165 cm, velvety and translucent skin, and bilateral venous
varicosities (Fig. 1C). The patient had a total of two preg-
nancies, the first uncomplicated, the second terminated at
about 4 months of gestation because of the presence of
the above mentioned aneurysm of the ascending aorta at
high dissection risk. She had recurrent wrist dislocations
in childhood. Proband's father suddenly died at the age of
33 years for unknown causes. The 26 years old proband's
daughter did not present valvular, aortic or other anoma-
lies during several echocardiographic evaluations. Her
clinical history included a pituitary adenoma and she suf-
fered from reactive hypoglycaemia and allergic rhinitis.
Recurrent left patella dislocations were reported, without
other signs of joint hypermobility. She showed mild myo-
pia.
In Patient 1, sequencing analysis of genomic DNA dis-
closed in exon 6 of the TGFBR1 gene the c.1052A>G tran-
sition, leading to the substitution of an aspartic acid with
a glycine in position 351 of the aminoacidic sequence
(p.Asp351Gly) (Fig. 2A). This novel missense mutation
was not detected in the proband's parents, suggesting that
it arose as a de novo event. In Patient 2 and in her daughter,
TGFBR2 genotyping disclosed the c.1529T>G transversion
in exon 7, resulting in the p.Ile510Ser missense mutation
(Fig. 2A). The proband's father was likely affected with
LDS, as he suddenly died at a young age. Both missense
mutations here identified were not detected in 250 chro-
mosomes of control Italian blood donors, and substituted
residues in the kinase domain of the proteins, which is
Molecular characterization of the patients by TGFBR1 and TGFBR2 sequencing on genomic DNA, obtained from whole periph- eral blood Figure 2
Molecular characterization of the patients by TGFBR1 and TGFBR2 sequencing on genomic DNA, obtained 
from whole peripheral blood. A) Sequence chromatogram of Patient 1, showing the position of the heterozygous 
c.1052A>G transition in TGFBR1 exon 6, leading to the p.Asp351Gly missense mutation, and chromatogram of Patient 2 show-
ing the heterozygous c.1529T>G transversion in TGFBR2 exon 7, resulting in the p.Ile510Ser missense mutation. B) The 
p.Asp351Gly and p.Ile510Ser mutations substitute in LDS patients an aspartic acid and an isoleucine residues that are evolu-
tionally conserved in TGFBR1 and TGFBR2 orthologues, respectively. Multiple sequence alignment was performed using CLUS-
TALW and PolyPhen.Orphanet Journal of Rare Diseases 2009, 4:24 http://www.ojrd.com/content/4/1/24
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highly conserved in the homologous of the receptor (Fig.
2B). Furthermore, in silico prediction algorithms, poly-
morphism phenotyping (PolyPhen) and sorting intoler-
ant from tolerant (SIFT) [3], characterized both the
p.Asp351Gly and p.Ile510Ser substitutions as damaging
and affecting protein function, respectively.
Patient 1 showed suggestive signs (i.e., marfanoid habitus
without fulfilled Ghent criteria for MFS, facial, skeletal,
cutaneous and cardiovascular involvement) consistent
with LDSI phenotype. Patient 2 showed the absence of
cardinal features of LDS, such as arterial tortuosity, bifid
uvula, hypertelorism, micrognathia, and joint hypermo-
bility. These observations, associated with the presence of
translucent skin and of marked venous varicosities, are
consistent with a LDSII phenotype. In particular, Patient 2
resembled vEDS for skin presentation and joint involve-
ment, that generally is less evident in vEDS than in other
EDS types and in LDS patients [2]. However, the straight
involvement of the thoracic aorta of Patient 2 is more sug-
gestive of an LDS rather than a vEDS phenotype, since in
vEDS the medium-sized arteries are more frequently
affected than aorta and great vessels [14]. So far, 21 LDSII
patients were reported, some of which did not show aortic
root dilatation, arterial tortuosity, or both [2,13,15].
Remarkably, the daughter of Patient 2 showed at 26 years
few disease signs, supporting previous observations in
LDS intrafamiliar variability.
In the TGFBRs-related disorders no genotype-phenotype
correlation has been drawn, and the prediction of the clin-
ical effects of different TGFBRs mutations remains diffi-
cult to envisage [1,9]. All the clinical entities caused by
mutations in TGFBRs genes should be considered a phe-
notypic continuum of the same disease, ranging from iso-
lated thoracic aneurysm to syndromic vascular rupture,
and LDS should be considered a complex syndrome char-
acterized by full penetrance (with very rare exceptions)
[2], marked variable intra- and inter-familiar expressivity,
allelic and genetic heterogeneity, pleiotropic effects, and
high incidence of de novo events. On the other hand, LDS
shows marked overlapping signs with other connective
tissue disorders, due to different gene defects and charac-
terized by vascular fragility, such as MFS (MIM 154700),
vEDS (MIM 130050), and arterial tortuosity syndrome
(ATS, MIM 208050), due to mutations in SLC2A10 gene
and characterized by facial features, aneurysm ruptures,
great vessels tortuosity, and pulmonary artery stenosis
[1,2,6,13,16]. The allelic heterogeneity, as well as the clin-
ical overlapping, could be related to the underlying patho-
physiology of LDS, MFS, and MFS2 syndromes, and
probably ATS, sharing alterations in similar molecular
pathways [1,2,16]. Indeed, in these disorders, aortic aneu-
rysm is associated with altered collagens deposition, elas-
tic fibers disarray, and increased TGFbeta signalling, and
is prevented by TGFbeta antagonists in the murine model
[1,2,5,16,17].
Conclusion
We report two novel mutations in the TGFBR1  and
TGFBR2  genes in two patients affected with LDS and
showing marked phenotypic variability. Due to the diffi-
culties in the clinical approach to a TGFBR-related disease,
among patients with vascular involvement, with or with-
out aortic root dilatation and LDS cardinal features, geno-
typing is mandatory to clarify the diagnosis, to assess the
management and the prognosis, and to satisfy counselling
issues.
Further genotype-phenotype studies in these connective
tissue disorders, together with the comprehension of the
role of the genetic factors responsible of the arterial wall
defects, will provide new insights in vascular diseases. The
pathogenesis, as well as the phenotype of LDS, could be
influenced by other genetic factors, either TGFBRs intra-
genic functional polymorphisms and different modifier
genes, encoding for TGFbeta pathway proteins, or compo-
nents of the vascular extracellular matrix.
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